Alessandro Strusi

Viterbo, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

A phase II study of nivolumab plus metformin in pre-treated metastatic renal cell carcinoma patients: NivoMet TWINS-GU002 Study.

A phase II study of nivolumab plus metformin in pre-treated metastatic renal cell carcinoma patients: NivoMet TWINS-GU002 Study.

Journal: Tumori
Published: October 30, 2025

Venous Thromboembolic Risk Does Not Increase After a Third Dose of SARS-CoV-2 mRNA-BNT162b2 Vaccine in Cancer Patients Receiving Active Systemic Therapies: Updated Results from the Vax-On-Third-Profile Study.

Venous Thromboembolic Risk Does Not Increase After a Third Dose of SARS-CoV-2 mRNA-BNT162b2 Vaccine in Cancer Patients Receiving Active Systemic Therapies: Updated Results from the Vax-On-Third-Profile Study.

Journal: Vaccines
Published: February 16, 2025

The Clinical Role of Hypoxia Inducible Factor (HIF) Inhibition in Renal Cancer: A Focus on Belzutifan.

The Clinical Role of Hypoxia Inducible Factor (HIF) Inhibition in Renal Cancer: A Focus on Belzutifan.

Journal: Current cancer drug targets
Published: July 04, 2024

Highlights from the 2024 ASCO Genitourinary Symposium: focus on urothelial and prostate cancer.

Highlights from the 2024 ASCO Genitourinary Symposium: focus on urothelial and prostate cancer.

Journal: Expert review of anticancer therapy
Published: June 27, 2024

The incidence and relative risk of major adverse cardiovascular events and hypertension in patients treated with immune checkpoint inhibitors plus tyrosine-kinase inhibitors for solid tumors: a systemic review and meta-analysis.

The incidence and relative risk of major adverse cardiovascular events and hypertension in patients treated with immune checkpoint inhibitors plus tyrosine-kinase inhibitors for solid tumors: a systemic review and meta-analysis.

Journal: Expert review of anticancer therapy
Published: June 16, 2024

The Role of the Complement in Clear Cell Renal Carcinoma (ccRCC)-What Future Prospects Are There for Its Use in Clinical Practice?

The Role of the Complement in Clear Cell Renal Carcinoma (ccRCC)-What Future Prospects Are There for Its Use in Clinical Practice?

Journal: Cancers
Published: December 15, 2023

Avelumab Plus Intermittent Axitinib in Previously Untreated Patients with Metastatic Renal Cell Carcinoma. The Tide-A Phase 2 Study.

Avelumab Plus Intermittent Axitinib in Previously Untreated Patients with Metastatic Renal Cell Carcinoma. The Tide-A Phase 2 Study.

Journal: European urology
Published: December 04, 2023

Theranostics revolution in prostate cancer: Basics, clinical applications, open issues and future perspectives.

Theranostics revolution in prostate cancer: Basics, clinical applications, open issues and future perspectives.

Journal: Cancer treatment reviews
Published: November 22, 2023

2023 ASCO genitourinary cancers symposium: focus on renal cell carcinoma.

2023 ASCO genitourinary cancers symposium: focus on renal cell carcinoma.

Journal: Expert review of anticancer therapy
Published: May 29, 2023

Post nephrectomy management of localized renal cell carcinoma. From risk stratification to therapeutic evidence in an evolving clinical scenario.

Post nephrectomy management of localized renal cell carcinoma. From risk stratification to therapeutic evidence in an evolving clinical scenario.

Journal: Cancer treatment reviews
Published: December 09, 2022

Unweaving the mitotic spindle: A focus on Aurora kinase inhibitors in lung cancer.

Unweaving the mitotic spindle: A focus on Aurora kinase inhibitors in lung cancer.

Journal: Frontiers in oncology
Published: August 23, 2022

Targeting hypoxia-inducible factor pathways in sporadic and Von Hippel-Lindau syndrome-related kidney cancers.

Targeting hypoxia-inducible factor pathways in sporadic and Von Hippel-Lindau syndrome-related kidney cancers.

Journal: Critical reviews in oncology/hematology
Published: April 12, 2022
Showing 1-12 of 12

Last Updated: 09/26/2026